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Abstract  Computed tomography (CT) in abdominal imaging has undergone great advances in recent years. The 
administration of iodinated contrast media (CM) has evolved along with the evolution of the CT equipment. The most 
common method for calculat ion of the CM volume in abdominal CT is based on total body weight (TBW), but in  this way 
some patients get a lower dose and some other patients get a higher dose that the optimal dose they need. In the literature there 
are many formulas to calculate the CM volume to be administered in abdominal CT, but practice shows that the variability of 
enhancement is wide. The main objective of this study is to verify  that the volume of intravenous CM in abdominal CT 
calculated on basis of lean body weight (LBW) allows good liver enhancement with small amplitude of variat ion around the 
mean, that is, with less variability in  enhancement than CM volume calcu lated on basis of TBW. In  conclusion the calculation 
of the volume of CM on basis of LBW translates into a low variability of liver enhancement–25.50 HU. In our results 96.05% 
of sample belongs to a good hepatic enhancement. If we stratify sample by groups of BMI, we also verify no significative 
differences between slims and fat patients when analysed mean hepatic enhancement. 
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1. Introduction 
The development of multidetector CT equipment (MDCT) 
with increased spatial and temporal resolution, with 
acquisition of large volumes in  a fraction of time prev iously 
needed, and the development of double head injectors, 
allowed for a revolution in abdominal CT imaging and 
improved diagnostic accuracy[1]. A low dose of iodinated 
CM results in low parenchymal enhancement and hence 
limits the diagnostic accuracy of the study. A high dose 
emphasizes lesions but increases cost and the likelihood of 
contrast media adverse reaction such as contrast-induced 
nephropathy (CIN). It would therefore be useful if a simple 
calculation method that leads to a more uniform hepatic 
enhancement among patients could be developed[2].  
In the literature there are many protocols to calcu late 
contrast volume admin istration in abdominal CT. The most 
common formulae calculate CM volume based upon the 
patient TBW. Other formulae do the same calculation based 
on the iodine concentration of the CM, using and iodine 
ratio of 0.521g per kilogram of body weight[3]. There are 
also centres that use a fixed volume of CM, no matter the  
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patient’s size or body weight[2].  
The most recent literature refers that calculat ing the CM 
volume based on the LBW may reduce patient-to-patient 
enhancement variability, while maintaining satisfactory 
hepatic enhancement. This method would  allow one to 
achieve consistent hepatic enhancement[4,5] and may 
contribute to the estimation of optimal iodine doses to be 
used in obese patients[6]. A d ifferent approach, using body 
fat percentage (BFP) as been advocated in one study as a 
good method of calculating CM volume, but BFP is 
correlated with the LBW and essentially assumes the same 
principle, that fat does not capture significant amounts of 
CM and can be d isregarded when calcu lating the optimal 
dose of CM to be injected[7].  
To measure hepatic enhancement the portal/venous phase 
is the best. Liver enhancement occurs 40/50s after aort ic 
enhancement. So there are two  forms to  acquire images in 
portal/venous phase: one uses an empirically delay of 70s or 
a more rigorous one uses a bolus-tracking program to 
determine the init iation[5, 8].  
Literature considers a good hepatic enhancement when 
the variation between hepatic density before administration 
of CM and hepatic enhancement after CM admin istration is 
around 50-60 HU[3,5,7]. The main object ive of this study is 
to verify if the volume of intravenous contrast medium in 
abdominal CT calculated on LBW allows good liver 
enhancement. To achieve this we define some specific 
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objectives: to find if this method avoids low doses in slim 
patients and overdoses in fat patients; to verify how the 
method of volume calcu late can influence de final volume 
(TBW/LBW), to verify if exist a correlat ion between 
hepatic enhancement calculates on basis of LBW and sex or 
age of individual. 
2. Material and Methods 
2.1. Explained Methods 
The data collection phase occurred between January and 
July 2011 in  The Imaging  Unit of Hospital da Boavista in 
Porto, Portugal. 
2.2. Patients 
This study was approved by the admin istration of the 
Hospital da Boavista in Porto. The inclusion criteria were: 
acceptance and signing of an informed consent for all 
patients, patients proposed to an abdominal CT with 
administration of contrast media in a venous/portal phase, 
20 gauge plastic intravenous catheter placed in an 
antecubital vein, inject ion rate of 3.5 mL/s and finally 
patients with orthostatic ability to measured and weighed. 
We excluded all exams with variations in the init ial 
protocol, patients with hepatic steatosis and patients without 
clear v isualization of hepatic veins in the venous phase (low 
cardiac debit). 
2.3. Estimated LBW 
For each patient a  sheet was created which recorded height 
and weight. The initial phase of the protocol was determine 
the value of LBW, estimated using the “Clinical Calculator” 
– The Medcalc©, which is based on the following formula: 
LBW (Men) = (1.10 x weight (kg)) - 128 (weight2 / (100 x 
height (m)) 2; LBW  (female) = (1.07 x weight (kg)) - 148 
(weight2 / (100 x height (m)) 2. 
2.4. Calculation of CM Volume 
We adopted the ratio of Kondo (2010), adapted to protocol 
of the Imaging Unit o f the Hospital da Boavista. In  Kondo’s 
study the author´s used 600 mg I /kg  of TBW  and reached a 
value of 812 mg I /kg of LBW[5]. Protocol of Hospital da 
Boavista uses 525 mg I /kg  of TBW  (1,5 mL/kg). Using the 
same reasoning our new value is 718 mg I /kg LBW (2 
mL/kg).  
2.5. Equipment and Material  
The imaging was performed  through a multidetector CT 
scanner (Siemens Somatom Sensation 40), sections at 1.2 
mm detector collimation, 1.5 mm per rotation table feed and 
1 p itch. Gantry rotation time was 0.5 s. We used Care Dose 
4D, with 250 effective mAs, 120 kV and the acquisition was 
with a soft kernel filter (kernel 30F medium s mooth) and 
abdominal window. The injection was performed by using a 
double head injector (Medtron Injekron CT2) allowing saline 
injection, immediately after in jection of CM. The contrast 
media used was Iobitridol (Xenetix ®), with a concentration 
of 350 mg I / mL, which mean 767.8 mg I/mL of solution. 
This CM is classified as water soluble, non-ionic and low 
osmolality. 
2.6. Acquisition Protocol  
All acquisitions were done using a protocol previously 
record in the CT console. The examination includes a control 
scan in the liver region and utilizat ion of a bolus-tracking 
program to determine the initiat ion time of the venous/portal 
phase. A region-of-interest (ROI) with 1 cm2 was placed in 
the abdominal aorta and the image acquisition 40 s after ROI 
measure 150HU. The literature says that a real venous/portal 
phase occurs 40 s after arterial phase[8]. The CM volume 
was calculated based on LBW with an inject ion of 40 mL of 
saline solution and a rate of 3.5 mL/s. 
2.7. Data Analysis 
Image analysis included three main stages, as described 
below. The first step consisted in checking all data sheets, 
confirming the values recorded on the data sheet (lean 
weight, calculat ing the CM volume) and also analysing all 
observations noted in the record susceptible to modify the 
result of the examination, for example, change in the 
protocol. The second was analysing all control scans (images 
without admin istration of CM) for measuring the density of 
the liver and spleen for evidence of hepatic steatosis (Figure 
1). This analysis was performed with Rad iAnt DICOM 
Viewer®. We used four ROI with 1 cm2, three in the liver 
and one in the spleen, so we can compare the liver density 
with the spleen density. The patients with liver density 
inferior to 40 HU and all patients with liver density superior 
to 40 HU but with less of 10 HU of spleen density were 
excluded[9, 10].   
 
Figure 1.  Example of measuring the density of the liver and spleen for 
evidence of hepatic steatosis, in images without CM 
In a third stage we analysed all images after CM 
administration to get our main variable. We selected a slice 
where liver appears in the major extension. We marked four 
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ROI’s (1cm2), three in the peripheral region of the liver, 
thereby preventing large vessels, and one in the spleen 
(Figure 2). Data was then entered into the database. The 
"hepatic enhancement" variable is the average of these three 
measurements. 
 
Figure 2.  Example of the method to measure liver enhancement, after CM 
administration 
2.8. Statistical Analysis 
Statistical analysis was performed using adequate 
software: Statistical Package for Social Sciences (SPSS, 
version 19.0). We used the analysis of frequencies to 
describe sample and analyse the distribution of hepatic 
enhancement. We used a Intraclass Correlation Coefficient 
(ICC) to validate data. Sample T-Test was used to verify  how 
the method of calcu lation (TBW or LBW) influences the 
volume. To  verify whether there was a statistically 
significant correlat ion between hepatic enhancement and age 
or sex we use Pearson correlat ion test. 
3. Results 
3.1. Patients 
The initial sample included 108 non-consecutive patients 
that met the enrolment criteria. Of 108 patients, 32 were 
excluded, due to changes to the protocol (8), unavailab ility 
of images (7), withdrawal o f a patient participating (1), debit 
cardiac alterations (8) and hepatic steatosis (8). The final 
sample consisted of 76 indiv iduals: 46 (60.5%) were male 
and 30 (39.5%) were female, aged between 19 and 87 years, 
a body weight between 45 and 93 kg and a height between 
140 and 186 cm, accord ing to Table 1. 
Table 1.  Sample characterization 
Sample characterization 
N=76 Minimum Maximum Mean Standard Desviation 
Age (year) 19 87 62.42 15.50 
Weight (kg) 45 93 67.76 9.87 
Height (cm) 140 186 165 9.19 
3.2. Intra-class Correlation Coefficients  
Since all measurements were performed by the same 
person, we calculated the intra-class correlation coefficients 
(ICC). An external evaluator analyzed 30% of the sample, 
selected randomly. Subsequently, these measurements were 
compared with the total sample, obtaining an ICC value 
of .909 for simple measures and .953 for average measures. 
We assume the measurements used as valid. 
3.3. Hepatic Enhancement 
Our results show a uniformity of hepatic enhancement in 
the total analysis. Comparing hepatic density after CM 
administration with hepatic enhancement before CM 
administration, results show an average increase of 54 HU 
(Table 2). The variation between the maximum and 
minimum values after CM administration was 25.50 HU; the 
hepatic density variation before CM administration was 27 
HU (Table 2). 
Table 2.  Hepatic density vs. hepatic enhancement 
N=76 Hepatic density (After CM) 
Hepatic 
enhancement 
(Before CM) 
Minimum 44.00 100.20 
Maximum 71.00 125.70 
Mean 56.43 110.20 
Variation in sample 27.00 25.50 
After analyse sample we verify that 96.05% of results 
belong to a good enhancement (Table 3). 
Table 3.  Sample distribution by three intervals of hepatic enhancement 
Enhancement intervals n % 
Low enhancement 
(< 100 HU) 0 0 
Good enhancement 
(100-120HU) 73 96.05 
O ver enhancement 
(> 120 HU) 3 3.95 
To understand the real difference in CM volume using this 
calculation method (LBW) and the most common method 
(TBW ), we compared the volume of the same patients using 
different methods. We used the value of CM volume used 
with LBW and estimate the volume of CM we would use if 
we use the TBW as the basis for calculat ing, based on the 
theory of 1.5 mL CM / kg of TBW. With Sample T-Test we 
verify  a lot of variations in  CM volumes with  different 
methods, (t (75) =2.934, p<.05, r=.913). Figure 3 is a  specific 
case of the sample, in which  four patients with the same 
TBW (66 kg), present different values of LBM and 
consequently different volumes of CM administered. But if 
we use the TBW method to calculate, volume will be always 
the same 99 mL. 
To analyse if this method avoid low doses in slim patients 
and overdoses in fat patients, we div ided the sample in 
 American Journal of Biomedical Engineering 2013, 3(6A): 22-26 25 
 
 
different classes of body mass index (BMI). We defined four 
classes as described in Table 4, and compared the averages 
of enhancement between each group. We found a uniform 
enhancement, particularly in patients who are overweight. 
The results are no significat ive to patients with low weight, 
because the sample only has one patient with a BMI below 
18.4 values. 
 
Figure 3.  MC Volume TBW/LBW 
Table 4.  Mean of hepatic enhancement in 4 groups of BMI 
Groups of BMI N Mean hepatic enhancement 
Standard 
deviation 
Low weight 
(≤ 18.4) 1 117.1 - 
Normal weight 
(18.5 – 24.99) 40 111.2 6.2 
O verweight 
(25.00 – 19.99) 31 108.8 4.9 
Obesity 
(≥ 30) 4 108.1 6 
The Pearson correlation coefficient revealed a 
significative negative correlation between hepatic 
enhancement and age, (r=.003, p<.05) and no significative 
correlation between hepatic enhancement and patient´s sex.  
4. Discussion 
Previous studies refer that to achieve an optimal hepatic 
enhancement the variation of HU will be around 50 – 60[1]. 
Since the density of normal liver also lies between 50 and 60 
HU, we can consider values between 100 and 120 HU 
belonging to a good range of hepatic enhancement. In Tab le 
3 is possible confirm that 96.05% of our results belong this 
range. Table 2 reveals also that the average variation of 
hepatic enhancement in  our sample was 53.77 HU. If vo lume 
of CM is calculated based on TBW, patients with the same 
body weight receive the same volume of CM, independently 
of height and fat percentage[10]. According Figure 3, if we 
calculate the CM volume on basis of LBW in four patients 
with same body weight we obtain different values; in this 
case volume can vary between 90 and 110 mL. It is also 
important to observe that this new method does not reduce 
the volume. It  optimizes it for each patient. We can also see 
in Figure 3 that to patients with same body weight, we may 
use higher or lower volumes, in comparing LBW to TBW. 
When we divided the patients into four groups of BMI, we 
verified that hepatic enhancement means are very  close, 
which means a low variability of values. Some authors also 
recommend not calculating CM volume on basis of TBW in 
patients below 60 kg and over 90 kg[8]. We verify no 
significative statistic differences between men and women, 
unlike some prev ious studies[11,12]. The exp lanation lies in 
the fact that the calculation of LBW takes into account the 
sex of the individual. We think that previous studies 
observed differences between sexes because they used TBW 
to calculate CM volume. On the other hand we find a 
statistically significant correlation between hepatic 
enhancement and age, which is possibly related with  changes 
in cardiac output that changes with age, and was not tested in 
this study. The fundamental point of this study is based on 
the following principle: when comparing vascularizat ion of 
fat tissues with other tissues, such as muscle and solid bodies, 
that have a greater vascularity and therefore need more 
volume of CM[1,2,7,13,14]. When someone gets fat, there is 
an increase exclusively of fat mass. Thus, if we increase the 
value of CM linearly with the increase in weight it will occur 
overdose of these individuals. This means that it’s arguable 
that we should increase the volume of CM in proportion to 
weight, making more sense to calculate based on LBW[1, 5, 
13,14]. The models fo r calculating the volume of CM based 
on the TBW try, in some way, to correct overdose imposing a 
maximum of CM volume. In some countries such as the 
United States, 120 mL is recommended as the maximum 
value. However, the relative values prevail and they aren’t 
adapted to the real individual constitution[4,5,15]. The 
division in four groups of BMI was important to demonstrate 
that there aren’t differences between slim and fat patients in 
hepatic enhancement. 
5. Conclusions 
In clinical practice, the calculat ion of the volume of CM 
on basis of LBW translates into a low variability of liver 
enhancement – 25.50 HU. In our results 96.05% of sample 
belongs to a good hepatic enhancement. If we stratify sample 
by groups of BMI, we also verify no significative differences 
between slims and fat patients when analysed mean hepatic 
enhancement. We suggest that this could replace the 
calculation based on TBW. 
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